Nothing Special   »   [go: up one dir, main page]

MD20150075A2 - Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale - Google Patents

Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale

Info

Publication number
MD20150075A2
MD20150075A2 MDA20150075A MD20150075A MD20150075A2 MD 20150075 A2 MD20150075 A2 MD 20150075A2 MD A20150075 A MDA20150075 A MD A20150075A MD 20150075 A MD20150075 A MD 20150075A MD 20150075 A2 MD20150075 A2 MD 20150075A2
Authority
MD
Moldova
Prior art keywords
heterocycle
substituted tetracyclic
methods
treatment
tetracyclic compounds
Prior art date
Application number
MDA20150075A
Other languages
English (en)
Russian (ru)
Inventor
Вэньшэн Юй
Тун
Джозеф А. КОЗЛОВСКИЙ
Олег Селютин
Лэй ЧЭНЬ
Чжэ-Хун КИМ
Д Ша
Разия Ризви
Бандарпалле Шанкар
Б Ху
Бинь Чжун
Дахай ВАН
Цзиньглай ХАО
Вэй
Цзи
Шуай Цзань
Original Assignee
Merck Sharp & Dohme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp filed Critical Merck Sharp & Dohme Corp
Publication of MD20150075A2 publication Critical patent/MD20150075A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Invenţia se referă la compuşi tetraciclici heterociclu-substituiţi noi cu formula (I):(I)şi la săruri farmaceutic acceptabile ale acestora, în care A, A', R2, R3 şi R5 au semnificaţiile definite în descriere. Invenţia se referă de asemenea la compoziţii cu conţinut de cel puţin un compus tetraciclic heterociclu-substituit şi la metode de utilizare a compuşilor tetraciclici heterociclu-substituiţi pentru tratamentul sau prevenirea infecţiei HVC la pacient.
MDA20150075A 2013-01-16 2013-12-31 Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale MD20150075A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/000038 WO2014110687A1 (en) 2013-01-16 2013-01-16 Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
PCT/CN2013/001676 WO2014110705A1 (en) 2013-01-16 2013-12-31 Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

Publications (1)

Publication Number Publication Date
MD20150075A2 true MD20150075A2 (ro) 2016-02-29

Family

ID=51208906

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150075A MD20150075A2 (ro) 2013-01-16 2013-12-31 Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale

Country Status (26)

Country Link
US (1) US9555038B2 (ro)
EP (1) EP2945952B1 (ro)
JP (3) JP6093451B2 (ro)
KR (1) KR101748974B1 (ro)
CN (1) CN105073755B (ro)
AP (1) AP2015008625A0 (ro)
AR (1) AR094496A1 (ro)
AU (1) AU2013374112B2 (ro)
BR (1) BR112015016325A2 (ro)
CA (1) CA2898049C (ro)
CL (1) CL2015001971A1 (ro)
CR (1) CR20150378A (ro)
DO (1) DOP2015000169A (ro)
EA (1) EA030554B1 (ro)
EC (1) ECSP15035530A (ro)
HK (1) HK1211290A1 (ro)
IL (1) IL239832A0 (ro)
MA (1) MA38315B1 (ro)
MD (1) MD20150075A2 (ro)
MX (1) MX356203B (ro)
PE (1) PE20151892A1 (ro)
PH (1) PH12015501560A1 (ro)
SG (1) SG11201505536RA (ro)
TN (1) TN2015000293A1 (ro)
TW (1) TW201441231A (ro)
WO (2) WO2014110687A1 (ro)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110687A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
US10457690B2 (en) 2015-06-04 2019-10-29 Merck Sharp & Dohme Corp. Process for preparing substituted tetracyclic heterocycle compounds
WO2017023714A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
US20180228828A1 (en) * 2015-08-04 2018-08-16 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
US20190002480A1 (en) * 2015-12-21 2019-01-03 Merck Sharp & Dohme Corp. Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases
WO2017181383A1 (en) 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Hepatitis c virus inhibitors
JP6958797B2 (ja) * 2016-06-21 2021-11-02 浙江柏拉阿図医薬科技有限公司 Ｃ型肝炎ウイルス阻害剤およびその使用
WO2018032468A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2018032467A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
CN109206396B (zh) * 2017-07-05 2023-03-28 上海迪赛诺化学制药有限公司 2-c-甲基-4,5-o-(1-甲基乙烯基)-d-阿拉伯糖酸乙酯的制备方法
CN109232612A (zh) * 2017-07-11 2019-01-18 周龙兴 抑制丙肝病毒的化合物、药物组合物及其用途
EP3870183A4 (en) * 2018-10-26 2022-07-20 Merck Sharp & Dohme Corp. FORMULATIONS OF ANTIVIRAL COMPOUNDS
WO2022266497A1 (en) * 2021-06-17 2022-12-22 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
MXPA06000372A (es) 2003-07-10 2006-03-30 Paradigm Therapeutics Ltd Compuestos de silicio y su uso.
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006046039A2 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
US20110104109A1 (en) 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
MX2008000462A (es) 2005-07-14 2008-03-10 Irm Llc Compuestos heterotetraciclicos como mimeticos de tpo.
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
FR2894963A1 (fr) 2005-12-16 2007-06-22 Inst Nat Sante Rech Med Nouveaux composes interagissant avec pea-15
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2694297A1 (en) 2007-08-09 2009-02-12 Merck Sharp & Dohme Corp. Silicon derivatives as histone deacetylase inhibitors
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
MX2010001650A (es) 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
CN102007122B (zh) 2008-02-13 2013-09-04 百时美施贵宝公司 作为丙型肝炎病毒抑制剂的咪唑基联苯基咪唑
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ME02024B (me) 2008-07-22 2015-05-20 Merck Sharp & Dohme Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze
WO2010041687A1 (ja) 2008-10-09 2010-04-15 コニカミノルタホールディングス株式会社 有機光電変換素子、太陽電池及び光センサアレイ
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CN102647909B (zh) 2008-12-03 2014-06-25 普雷西迪奥制药公司 Hcv ns5a的抑制剂
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
UA108351C2 (uk) * 2009-03-27 2015-04-27 Інгібітори реплікації вірусу гепатиту c
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
EP2435421A1 (en) 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
WO2012040923A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
JP2013538831A (ja) * 2010-09-29 2013-10-17 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウィルス感染治療のための四環式インドール誘導体
MX2013003634A (es) * 2010-09-29 2013-05-20 Merck Sharp & Dohme Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2014110688A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases

Also Published As

Publication number Publication date
WO2014110687A1 (en) 2014-07-24
CR20150378A (es) 2015-12-09
CN105073755B (zh) 2017-08-18
AR094496A1 (es) 2015-08-05
CL2015001971A1 (es) 2015-10-23
CA2898049C (en) 2018-04-17
JP2016510321A (ja) 2016-04-07
HK1211290A1 (en) 2016-05-20
KR101748974B1 (ko) 2017-06-19
ECSP15035530A (es) 2017-08-31
TW201441231A (zh) 2014-11-01
EP2945952A1 (en) 2015-11-25
MX2015009225A (es) 2015-10-15
SG11201505536RA (en) 2015-08-28
CN105073755A (zh) 2015-11-18
EA201591328A1 (ru) 2015-11-30
EA030554B1 (ru) 2018-08-31
US9555038B2 (en) 2017-01-31
AU2013374112B2 (en) 2016-11-17
TN2015000293A1 (en) 2016-10-03
JP6093451B2 (ja) 2017-03-08
JP6417380B2 (ja) 2018-11-07
MA38315B1 (fr) 2018-05-31
AP2015008625A0 (en) 2015-07-31
BR112015016325A2 (pt) 2017-08-22
PE20151892A1 (es) 2015-12-24
JP6148779B2 (ja) 2017-06-14
WO2014110705A9 (en) 2015-03-05
AU2013374112A1 (en) 2015-07-16
PH12015501560A1 (en) 2015-09-21
JP2017095450A (ja) 2017-06-01
MX356203B (es) 2018-05-18
IL239832A0 (en) 2015-08-31
EP2945952A4 (en) 2016-07-20
MA38315A1 (fr) 2017-02-28
EP2945952B1 (en) 2019-08-28
KR20150104630A (ko) 2015-09-15
DOP2015000169A (es) 2015-12-31
WO2014110705A1 (en) 2014-07-24
JP2017075158A (ja) 2017-04-20
CA2898049A1 (en) 2014-07-24
US20150335648A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
NZ703064A (en) Inhibitors of hepatitis c virus
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
NZ742681A (en) Amide compounds for the treatment of hiv
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500347A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MY182590A (en) Benzylamine derivatives
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
MY197698A (en) Oxysterols and methods of use thereof
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
MX2015000163A (es) Nuevos indazoles para el tratamiento y la profilaxis de la infeccion por virus sincitial respiratorio.
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)